VERIFIEDEconomic Times News·25 May 2026neutral

Margin pressure, slower growth outlook may cap upside for Sun Pharma stock

AI Summary

·Sun Pharma reported strong revenue and profit growth in the March quarter.
·EBITDA margins faced pressure due to increased investments and lower milestone income.
·The company anticipates range-bound margins and moderating revenue growth in FY27.